Disruptive Therapeutics.
Advancing Science.
Making a Difference.

SBP-101

Compelling preclinical study results

Preclinical studies have shown that SBP-101 produces superior anti-tumor activity in human cancer cell lines compared to gemcitabine or nab-paclitaxel, alone or in combination, standard of care chemotherapy drugs used to treat pancreatic cancer.

Sun BioPharma’s novel approach

The Company believes that SBP-101 will have a distinct advantage over current pancreatic cancer* therapies in that it specifically targets the exocrine pancreas and can cause ablation, or pharmaceutical resection, of the acinar cells, as well as the primary and metastatic pancreatic cancer, while leaving the insulin-producing islet cells and most non-pancreatic tissue unharmed.  Most current cancer therapies (including chemotherapy, radiation or surgery) are associated with significant side effects that further reduce the patient’s quality of life. Read More »
*pancreatic ductal adenocarcinoma

Compound & Clinical Targets

home1

SBP-101

Read more

pancreatic cancer

Pancreatic Cancer

Read more

home3

Pancreatitis

Read more

Leadership

David Kaysen

President and Chief Executive Officer

Read more

Scott Kellen

Vice President and Chief Financial Officer

Read more

Cheryl Baker, Ph.D

Cancer Cellular Biology Consultant

Read more

Michael Cullen, MD

Executive Chairman of the Board

Read more

Thomas Neenan, Ph.D.

Chief Scientific Officer

Read more

Tammy Groene

VP of Operations & Corporate Secretary

Read more

Suzanne Gagnon, MD

Chief Medical Officer

Read more

Ajit Shah, Ph.D.

VP Pharmacology

Read more

Andy Kiorpes, Ph.D.

Toxicology Consultant

Read more

Collaborations

  • Home
    University of Florida
  • Home
    Translational Genomics Research Institute
  • Home
    Adelaide Cancer Centre
  • Home
    Fred Hutchinson Cancer Center
  • Home
    Cedar-Sinai Medical Center
  • Home
    Charles River
  • Home
    CNIO
  • Home
    University of Minnesota
  • Home
    Moffitt Cancer Center
  • Home
    Ohio State James Cancer Center